Sandro Wealth Management LLC Makes New $2.09 Million Investment in Thermo Fisher Scientific Inc. $TMO

Key Points

• Sandro Wealth Management acquired a new position of 3,606 shares of Thermo Fisher valued at approximately $2.09 million, making the stock about 1.7% of the fund's portfolio and its 17th-largest holding.
• Thermo Fisher beat quarterly expectations with $5.44 EPS vs. $5.25 expected and $11.01B revenue, and set FY2026 EPS guidance of 24.640–25.120 (analysts' consensus ~24.85).
• The company recently raised its quarterly dividend to $0.47 ($1.88 annualized, ~0.4% yield), while insiders — including CEO Marc N. Casper — sold shares (the CEO sold 5,000 shares); institutional ownership is about 89%.

Sandro Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 3,606 shares of the medical research company's stock, valued at approximately $2,089,000. Thermo Fisher Scientific comprises about 1.7% of Sandro Wealth Management LLC's portfolio, making the stock its 17th biggest holding.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock worth $19,778,774,000 after acquiring an additional 288,296 shares during the last quarter. Capital World Investors boosted its holdings in Thermo Fisher Scientific by 7.4% during the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock worth $4,988,132,000 after acquiring an additional 706,572 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Thermo Fisher Scientific by 21.0% during the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock worth $2,874,069,000 after acquiring an additional 1,028,125 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Thermo Fisher Scientific by 54.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock worth $1,732,422,000 after buying an additional 1,262,967 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Thermo Fisher Scientific by 5.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,087,666 shares of the medical research company's stock worth $1,789,148,000 after buying an additional 150,668 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $469.39 on Friday. The company has a market cap of $174.43 billion, a PE ratio of 25.80, a price-to-earnings-growth ratio of 2.12 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The firm's 50-day simple moving average is $496.11 and its two-hundred day simple moving average is $547.71.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion for the quarter, compared to analysts' expectations of $10.86 billion. During the same period in the prior year, the business posted $5.15 earnings per share. The company's revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were given a dividend of $0.47 per share. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.34%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TMO. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. TD Cowen cut their price target on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating on the stock in a report on Friday, January 30th. Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating on the stock in a report on Friday, April 24th. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a "strong-buy" rating in a report on Friday, April 24th. Finally, Morgan Stanley reissued an "overweight" rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Buy" and an average target price of $623.05.

Insider Activity

In related news, CEO Marc N. Casper sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 5,800 shares of company stock worth $2,963,544. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.